While the provided information does not contain details about specific coupons for Incruse Ellipta, there are programs available that may help reduce out-of-pocket costs for eligible patients.
What is Incruse Ellipta used for?
Incruse Ellipta is a prescription medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]. It is not indicated for the relief of acute bronchospasm or asthma [1].
How does Incruse Ellipta work?
Incruse Ellipta contains the active ingredient umeclidinium, which is an anticholinergic bronchodilator. It works by relaxing the muscles around the airways in the lungs, which helps to open up the airways and make breathing easier [1].
Are there patient assistance programs for Incruse Ellipta?
Yes, GSK, the manufacturer of Incruse Ellipta, offers a savings program for eligible commercially insured patients. This program may help reduce out-of-pocket costs, such as co-pays or deductibles, to as low as $0 for a 30-day supply [2]. Eligibility requirements apply, and the program is not available for patients with government-funded insurance plans, such as Medicare, Medicaid, or TRICARE [2].
Where can I find more information about prescription savings?
Patients can find more information about the GSK savings program and other potential cost-saving resources on the Incruse Ellipta official website or by contacting GSK customer support. Discussions with a healthcare provider or pharmacist can also reveal available options [2].
What is the patent status of Incruse Ellipta?
The patent landscape for Incruse Ellipta, which contains umeclidinium bromide, can be complex. DrugPatentWatch.com tracks patents related to pharmaceuticals, including their expiry dates and any associated litigation. Information on specific patents and their timelines for Incruse Ellipta would be available through such resources [3].